Thermo Fisher Scientific
+ Follow
Thermo Fisher Scientific Competitors & Alternatives
Thermo Fisher Scientific competitors and alternatives include Agilent Technologies, Danaher Corporation, etc.…
Jump
- Stock Price
- Market Cap
- Employees
-
Income Statement
- Revenue
- Revenue by Product / Services
- Revenue by Geography
- Research and Development
- Operating Income
- Tax Rate (%)
- Net Income
-
Assets & Liabilities | Cash Flow
- Total Assets
- Total Liabilities
- Capital Expenditures (Capex)
-
Profitability
- Operating Income Margin (%)
- Net Income Margin (%)
- EBITDA
- Free Cash Flow (FCF)
-
Ratios
- Return on Equity (ROE)
- Return on Assets (ROA)
- Debt to Equity
-
Valuation
- Enterprise value
- Enterprise value to Revenue
- Enterprise value to EBITDA
Ticker
TMO
A
DHR
Headquarter
Waltham
,MA
US
Santa Clara
,CA
US
Washington
,DC
US
CEO
Mr. Marc N. Casper
Mr. Rodney Gonsalves
Mr. Rainer M. Blair
Industry
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Stock Price
Stock Price
Market Cap
$203.50B
$38.75B
$169.62B
Employees
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Employees
- 130.00K
- 130.00K
- 122.00K
- 18.10K
- 18.10K
- 17.90K
- 81.00K
- 63.00K
Y/Y
62.5%
0%
6.15%
6.47%
0%
1.1%
1.25%
22.22%
Income Statement
Revenue
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Revenue
- $39.21B
- $44.92B
- $42.86B
- $6.85B
- $6.83B
- $6.51B
- $31.47B
- $23.89B
Y/Y
21.71%
14.55%
4.58%
8.37%
0.22%
4.73%
6.85%
24.09%
Revenue by Products / Services
Revenue by Geography
Research and Development
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Research and Development
- $1.41B
- $1.47B
- $1.34B
- $467.00M
- $481.00M
- $479.00M
- $1.75B
- $1.50B
Y/Y
19.05%
4.62%
9.11%
5.9%
3%
0.42%
0.17%
13.87%
Operating Income
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Operating Income
- $10.03B
- $8.39B
- $6.86B
- $1.62B
- $1.35B
- $1.49B
- $8.69B
- $5.20B
Y/Y
28.66%
16.3%
18.28%
20.12%
16.56%
10.22%
16.38%
40.12%
Tax Rate (%)
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Tax Rate (%)
- 13.00%
- 9.00%
- 5.00%
- 17.00%
- 7.00%
- 15.00%
- 13.00%
- 16.00%
Y/Y
6.63%
28.47%
49.72%
50.68%
55.54%
106.36%
20.66%
24.96%
Net Income
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Net Income
- $7.73B
- $6.95B
- $6.00B
- $1.25B
- $1.24B
- $1.29B
- $7.21B
- $4.76B
Y/Y
21.18%
10.03%
13.74%
3.64%
1.12%
3.95%
12.06%
33.92%
Assets & Liabilities | Cash Flow
Total Assets
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Total Assets
- $95.12B
- $97.15B
- $98.73B
- $10.53B
- $10.76B
- $11.85B
- $84.35B
- $84.49B
Y/Y
37.76%
2.14%
1.62%
1.62%
2.19%
10.06%
1.4%
0.16%
Total Liabilities
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Total Liabilities
- $54.15B
- $53.01B
- $51.88B
- $5.23B
- $4.92B
- $5.95B
- $34.26B
- $31.00B
Y/Y
56.79%
2.11%
2.12%
1.67%
5.91%
20.94%
9.86%
9.52%
Capital Expenditures (Capex)
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Capital Expenditures (Capex)
- -$2.52B
- -$2.24B
- -$1.48B
- -$291.00M
- -$298.00M
- -$378.00M
- -$1.15B
- -$1.38B
Y/Y
71.17%
11.1%
34.06%
53.97%
2.41%
26.85%
10.97%
20.05%
Profitability
Operating Income Margin (%)
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Operating Income Margin (%)
- 25.57%
- 18.69%
- 16.00%
- 23.63%
- 19.76%
- 22.86%
- 27.61%
- 21.77%
Y/Y
5.7%
26.91%
14.39%
10.83%
16.38%
15.69%
8.92%
21.15%
Net Income Margin (%)
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Net Income Margin (%)
- 19.70%
- 15.47%
- 13.99%
- 18.31%
- 18.15%
- 19.80%
- 22.91%
- 19.94%
Y/Y
0.45%
21.47%
9.57%
4.39%
0.87%
9.09%
4.9%
12.96%
EBITDA
2020 | 10192000000.00 |
---|---|
2021 | 12964000000.00 |
2022 | 11941000000.00 |
2023 | 11079000000.00 |
2021 | 1725000000.00 |
---|---|
2022 | 1994000000.00 |
2023 | 1703000000.00 |
2024 | 1488000000.00 |
2021 | 10007000000.00 |
---|---|
2022 | 9712000000.00 |
2023 | 7499000000.00 |
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
EBITDA
- $12.96B
- $11.94B
- $11.08B
- $1.99B
- $1.70B
- $1.49B
- $9.71B
- $7.50B
Y/Y
27.2%
7.89%
7.22%
15.59%
14.59%
12.62%
2.95%
22.79%
Free Cash Flow (FCF)
2020 | 6815000000.00 |
---|---|
2021 | 7020000000.00 |
2022 | 6911000000.00 |
2023 | 6927000000.00 |
2021 | 1296000000.00 |
---|---|
2022 | 1021000000.00 |
2023 | 1474000000.00 |
2024 | 1373000000.00 |
2021 | 7064000000.00 |
---|---|
2022 | 7367000000.00 |
2023 | 5781000000.00 |
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Free Cash Flow (FCF)
- $7.02B
- $6.91B
- $6.93B
- $1.02B
- $1.47B
- $1.37B
- $7.37B
- $5.78B
Y/Y
3.01%
1.55%
0.23%
21.22%
44.37%
6.85%
4.29%
21.53%
Ratios
Return on Equity (ROE)
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Return on Equity (ROE)
- 18.94%
- 15.80%
- 12.83%
- 23.64%
- 21.21%
- 21.85%
- 14.39%
- 8.91%
Y/Y
2.54%
16.58%
18.8%
5.3%
10.28%
3.02%
1.05%
38.08%
Return on Assets (ROA)
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Return on Assets (ROA)
- 8.12%
- 7.15%
- 6.07%
- 11.91%
- 11.52%
- 10.88%
- 8.55%
- 5.64%
Y/Y
12.03%
11.95%
15.1%
5.4%
3.27%
5.56%
10.61%
34.04%
Debt to Equity
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Debt to Equity
- 85.03%
- 78.42%
- 74.70%
- 52.20%
- 46.79%
- 57.48%
- 39.29%
- 34.41%
Y/Y
34.99%
7.77%
4.74%
3.08%
10.36%
22.85%
19.98%
12.42%
Valuation
Enterprise Value
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Enterprise value
- $293.29B
- $241.83B
- $231.72B
- $43.08B
- $31.54B
- $39.98B
- $184.28B
- $184.05B
Y/Y
49.74%
17.54%
4.18%
12.06%
26.8%
26.77%
19.17%
0.12%
Enterprise value to Revenue
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Enterprise value to Revenue
- 7.48
- 5.38
- 5.41
- 6.29
- 4.62
- 6.14
- 5.86
- 7.70
Y/Y
23.04%
28.01%
0.42%
18.85%
26.64%
33.06%
24.36%
31.57%
Enterprise value to EBITDA
Years
- 2021
- 2022
- 2023
- 2022
- 2023
- 2024
- 2022
- 2023
Enterprise value to EBITDA
- 22.62
- 20.25
- 20.92
- 21.61
- 18.52
- 26.87
- 18.97
- 24.54
Y/Y
17.73%
10.48%
3.28%
23.92%
14.29%
45.08%
16.72%
29.35%